XTNT stock trades around recent lows as Xtant Medical revenue climbs and losses narrow

Xtant Medical Holdings Inc. (ISIN US98420U1051), which trades on Nasdaq under the ticker XTNT, sits in a complex position for investors: XTNT stock is hovering near its 52-week low, while the company has been reporting improving fundamentals with higher revenue and a reduced net loss in its most recent financial year. For a micro-cap medtech issuer focused on spinal and orthopaedic biologics, this combination of a depressed share price and operational progress is a key part of the current investment narrative.

Revenue up versus prior year

Xtant Medical Holdings Inc. is a US-based medical technology company that develops and markets regenerative spinal and orthopaedic implant systems, with its primary listing on Nasdaq under the symbol XTNT. According to the company’s investor information for the 2024 financial year, Xtant Medical reported annual revenue of approximately $102 million for 2024, an increase from roughly $93 million in 2023, marking year-on-year revenue growth of about 10%. This uplift in revenue reflects a gradual expansion in demand for the company’s biologic products and implant solutions across its core hospital and surgery-center customer base.

In addition to the top-line growth, Xtant Medical’s filings indicate that the company reduced its net loss in 2024 compared with the prior year. For 2024, the net loss was in the region of $6 million, improving from roughly $9 million in 2023, which means the loss narrowed by about $3 million year-on-year. This narrowing loss illustrates that operational leverage and cost discipline are beginning to show up in the bottom line, even though the company has not yet reached overall profitability. The improvement is relevant for investors because it suggests a trajectory toward break-even if the current revenue growth and margin trends can be sustained.

The company’s gross margin in 2024 also improved modestly compared with 2023, supported by a more favorable product mix and measured cost control in manufacturing and distribution. While exact gross margin percentages vary across segments and quarters, the direction of travel over the last reported year has been positive, which helps to reinforce the overall picture of incremental financial progress. For a micro-cap issuer in the medical device space, a combination of rising revenue and better margins is often an important precondition for market confidence.

XTNT stock near 52-week low and market capitalization under $100 million

From a market perspective, XTNT stock has not yet fully reflected the company’s operational improvements. As of early July 2026, public quote data shows XTNT trading close to $0.40 per share on Nasdaq, which is near the lower end of its 52-week range between roughly $0.35 and $0.90. This price level translates into a market capitalization of around $70 million, using the latest available share count from the company’s filings and the prevailing market price. For investors, this places Xtant Medical firmly in the micro-cap category, where liquidity can be limited and volatility is often higher than for larger peers.

The fact that XTNT stock is trading near its 52-week low while revenue and margins have improved raises questions about how the market is discounting future growth and capital requirements. A share price in the sub-$1 range can also attract attention because Nasdaq listing rules require issuers to maintain certain minimum bid levels, and although Xtant Medical has previously navigated listing compliance issues, any sustained period of trading far below $1 may again place listing status on the radar. For now, however, the company continues to trade on Nasdaq and its investor-relations materials emphasize ongoing efforts to strengthen its financial profile.

When comparing Xtant Medical’s valuation with that of larger medtech peers, the disparity is evident. While mid- and large-cap medical device companies often trade at price-to-sales multiples of two to four times or higher, Xtant Medical’s implied price-to-sales multiple based on its roughly $102 million in 2024 revenue and a market capitalization of around $70 million is below one times sales. This low multiple reflects both the company’s loss-making status and the perceived risk associated with its size and niche focus, but it also means that if the company can sustain revenue growth and continue to narrow its losses, there is room for valuation normalization over time.

Spinal biologics products support revenue base

Xtant Medical’s revenue base is primarily built on biologic products and implant systems used in spinal fusion and other orthopaedic procedures. The company markets a portfolio of allograft-based biologics, demineralized bone matrix solutions, and complementary hardware that surgeons use to treat spinal pathologies such as degenerative disc disease, deformities, and trauma. These products are typically supplied to hospitals and ambulatory surgery centers, where they compete with offerings from larger medical device companies and other specialty biologics providers.

While individual product line revenues are not always broken out in detail in the company’s summary materials, spinal biologics and related implants represent the core driver of Xtant Medical’s roughly $102 million revenue figure in 2024. The company’s focus on regenerative biologics is designed to position it in a niche where clinical outcomes and surgeon familiarity drive adoption, but where pricing pressure and reimbursement dynamics must be managed carefully. For investors, understanding this product mix is important because biologics can carry higher gross margins than commoditized hardware, giving management a lever to improve overall profitability if volume growth continues.

XTNT stock price and market context

XTNT stock, with its approximate price of $0.40 per share as of early July 2026, reflects both company-specific factors and broader conditions in the small-cap medtech segment. In recent years, higher interest rates and a preference for larger, more liquid names have often weighed on micro-cap healthcare stocks, even when those issuers report improving operational metrics. Xtant Medical’s valuation at less than one times trailing revenue is therefore partly a function of investor risk appetite in this market environment, as well as the company’s own history of losses and capital raises.

One key consideration for shareholders is the potential need for future funding. Loss-making medtech companies frequently rely on equity or convertible debt offerings to finance growth, research, and working capital. Xtant Medical’s narrowed net loss of roughly $6 million in 2024 compared with $9 million in 2023 is encouraging, but the company has not yet reported positive net income or free cash flow. This reality means that any improvement in the stock price could be influenced by expectations about future dilution as well as operational progress. Investors often monitor the company’s balance sheet metrics, such as total debt and cash reserves, alongside revenue growth and margin trends to assess the sustainability of the business model.

Despite these challenges, the combination of rising revenue, improving gross margin, and a lower net loss indicates that Xtant Medical is making tangible progress on its turnaround efforts. The market’s cautious stance, visible in the sub-$1 share price and modest market capitalization of about $70 million, underscores that this progress remains a work in progress rather than a completed transformation. For many small-cap healthcare names, it is only when revenue growth accelerates further and profitability comes into view that the share price begins to re-rate meaningfully.

Representative product line in spinal care

Among Xtant Medical’s range of offerings, its spinal biologics portfolio is a representative example of the products that underpin the company’s revenue base. These biologics are used in spinal fusion procedures to promote bone growth and structural stability, often in combination with metallic hardware such as screws and rods. Xtant Medical’s positioning in this segment relies on a combination of clinical efficacy, surgeon familiarity, and distribution relationships with healthcare providers.

From an investor perspective, the spinal biologics segment is important because it can influence both growth and margins. If Xtant Medical can expand the use of its biologic implants in more procedures and across more facilities, incremental revenue gains can be achieved without proportionally increasing fixed costs, thereby supporting higher operating leverage. At the same time, competition from larger medtech companies in spinal implants and biologics means that the company must continue to invest in product development, evidence generation, and customer support to defend and grow its share of the market.

XTNT stock price snapshot and closing view

Looking at XTNT stock at a high level, the current approximate price of $0.40 per share on Nasdaq, near the 52-week low of about $0.35, stands in contrast to the company’s reported 2024 revenue of roughly $102 million and a net loss that has narrowed by around $3 million versus 2023. This juxtaposition between a depressed share price and improving fundamentals encapsulates the risk-reward profile that small-cap medtech investors often have to evaluate.

For Xtant Medical, the next phase of its development will likely be judged on whether it can sustain revenue growth, continue to improve margins, and eventually move closer to break-even at the net income level. XTNT stock’s low valuation and micro-cap status mean that news on orders, product adoption, and capital structure can have an outsized effect on the share price. As things stand, however, the company’s financial trends over the 2023 to 2024 period provide a data-backed narrative of progress that contrasts with the current subdued valuation on the market.